Lupin’s Nagpur Facility Cleared by US FDA with Zero Observations

announced that the US FDA has completed its pre-approval inspection of the company’s Nagpur Unit-1 (oral solid dosage facility), conducted between November 10 and 14, 2025, with zero Form 483 observations. This clean outcome reflects strong compliance standards and consistent operational discipline at the facility. Achieving a no-observation inspection is a meaningful positive from a regulatory standpoint, as it supports Lupin’s product pipeline approvals in the US market and reinforces its overall manufacturing credibility. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.